NCT04973657 - A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

October 9, 2024

Study Completion Date

November 8, 2024

Conditions

Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

Interventions

DRUG

VK0214

API in capsule

OTHER

Placebo

API in capsule

Trial Locations (9)

Viking Clinical Site 210, Milan

Viking Clinical Site 201, Baltimore

Viking Clinical Site 207, Gainesville

Viking Clinical Site 214, Bordeaux

Viking Clinical Site 215, Montpellier

Viking Clinical Site 203, Palo Alto

Viking Clinical Site 205, Seattle

Viking Clinical Site 209, Leipzig

Viking Clinical Site 212, London

All Listed Sponsors

lead

Viking Therapeutics, Inc.

INDUSTRY